Trial Profile
An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate (Copaxone ®) on Girls With Rett Syndrome
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Rett syndrome
- Focus Proof of concept; Therapeutic Use
- 03 Feb 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 27 Jan 2014 New trial record